GlaxoSmithKline

GlaxoSmithKline moves ahead with its planed cost saving strategy and cuts 650 jobs in North Carolina, according to

GSK cuts 650 jobs in the US

https://pharmaphorum.com/news/glaxosmithkline-cuts-650-jobs/

GlaxoSmithKline/ News

GSK’s Indian Horlicks sale may fetch over $4 billion

Piotr Wnuk GlaxoSmithKline, Horlicks 0 Comment

GlaxoSmithKline (GSK) has accelerated the review of its Horlicks business in India, hoping to sell it for over

GSK’s Indian Horlicks sale may fetch over $4 billion

https://pharmaphorum.com/news/gsk-indian-horlicks-sell-might-fetch-4-billion/

GlaxoSmithKline/ News

GSK appoints former HSBC exec Iain Mackay as CFO

Richard Staines GlaxoSmithKline, jobs 0 Comment

GlaxoSmithKline has appointed HSBC’s Iain Mackay as its next chief financial officer, replacing Simon Dingemans, who is to

GSK appoints former HSBC exec Iain Mackay as CFO

https://pharmaphorum.com/news/gsk-appoints-former-hsbc-exec-iain-mackay-cfo/

GlaxoSmithKline/ News/ News/ R&D/ Top pharmaceutical companies/ Top stories

GSK signs $300m R&D deal with 23andMe

Piotr Wnuk dna, genetic testing, GlaxoSmithKline 0 Comment

GlaxoSmithKline signed a $300 million research and development deal with mail gene profiling company 23andMe, gaining access to

GSK signs $300m R&D deal with 23andMe

https://pharmaphorum.com/r-d/gsk-welcomes-23andmes-dna-database/

GlaxoSmithKline/ News/ Top pharmaceutical companies/ UK & Europe/ US

GSK could split amid pressure from investors – report

Piotr Wnuk GlaxoSmithKline, Philip Hampton 0 Comment

GlaxoSmithKline’s chairman, Philip Hampton, may be considering splitting the company amid pressure from top investors to separate the

GSK could split amid pressure from investors – report

https://pharmaphorum.com/news/gsk-chairman-raises-break-prospect/

GlaxoSmithKline/ News

GSK’s blockbuster HIV drug linked with birth defects

Richard Staines GlaxoSmithKline, HIV, safety, ViiV 0 Comment

Regulators issue warning after preliminary study findings

GSK’s blockbuster HIV drug linked with birth defects

https://pharmaphorum.com/news/gsk-blockbuster-hiv-drug-linked-with-birth-defects/

GlaxoSmithKline/ News/ UK & Europe

FDA approves expanded use for GSK’s COPD triple therapy

Richard Staines COPD, GlaxoSmithKline, respiratory 0 Comment

GSK is aiming to revive its respiratory drugs franchise

FDA approves expanded use for GSK’s COPD triple therapy

https://pharmaphorum.com/news/fda-approves-expanded-use-for-gsks-copd-triple-therapy/

GlaxoSmithKline/ M&A/ News

GSK to pay $13bn for Novartis stake in OTC joint venture

Richard Staines GlaxoSmithKline, M&A, Novartis, OTC 0 Comment

GlaxoSmithKline is to buy out Novartis from their over-the-counter joint venture, and may sell its Horlicks business to

GSK to pay $13bn for Novartis stake in OTC joint venture

https://pharmaphorum.com/news/gsk-wants-take-control-otc-joint-venture/

GlaxoSmithKline/ Market Access/ News/ News/ News/ R&D/ R&D/ UK & Europe

Verona to take COPD hopeful into phase 3

Richard Staines Chiesi, COPD, GlaxoSmithKline, R&D, respiratory 0 Comment

Verona Pharma is to take lung drug RPL554 into late clinical development after a successful phase 2b trial.

Verona to take COPD hopeful into phase 3

https://pharmaphorum.com/market-access-2/verona-to-take-copd-hopeful-into-phase-3/

1 2 3 4

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com

Trending

GlaxoSmithKline

Login